Reynaud has 13 years’ experience in finance. For five years, he was initially involved in financing business companies in a financial institution, before overseeing several corporate finance transactions (fund-raising transactions, mergers and acquisitions) as chief financial and administrative officer of companies in a variety of sectors including medical devices and renewable energies. His most recent appointment was at Global Bioenergies, a listed industrial biology company.
Reynaud’s main role will be to handle the company’s financial and administrative affairs, working closely with the CEO.
“It is a unique opportunity to join Safe Orthopaedics just as the company has reported an increase in its third-quarter revenues of over 63 percent year-on-year and is expanding its business worldwide,” Reynaud said.
“Together with his expertise in finance, François-Henri’s appointment as chief financial and administrative officer brings to the table his experience of establishing and building up international subsidiaries just as Safe Orthopaedics embarks on a new phase of expansion to accelerate its growth and business development,” CEO Pierre Dumouchel added.
Founded in 2010, Safe Orthopaedics is a French medical technology company that develops spinal implants and associated single-use instruments. Through this approach, these products eliminate all risk of contamination, reduce infection risks and facilitate a minimally-invasive approach for trauma and degenerative pathologies—benefiting patients. Protected by 17 patent families, the SteriSpineTM kits are CE-marked and approved by the U.S. Food and Drug Administration. The company is based at Eragny-sur-Oise (Val d’Oise department), and has 34 employees.